Supernus Pharmaceuticals | SUPN - Current Assets


Supernus Pharmaceuticals reported $593.89M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Abbott USD 26B 1.16B Dec/2025
ANI Pharmaceuticals USD 698.4M 95.77M Sep/2025
Aurora Cannabis CAD 423.84M 41.46M Sep/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Canopy Growth CAD 445.82M 142.46M Sep/2025
Cara Therapeutics USD 43.13M 4.18M Jun/2025
Corcept Therapeutics USD 541.13M 98.02M Sep/2025
Eisai JPY 840.88B 50.18B Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Novo Nordisk DKK 172.45B 9.43B Dec/2025
Pacira USD 562.75M 182.86M Sep/2025
Perrigo USD 2.88B 264.2M Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
Supernus Pharmaceuticals USD 593.89M 144.98M Sep/2025
United Therapeutics USD 3.49B 332.9M Sep/2025
Xeris Pharmaceuticals USD 224.02M 38.44M Sep/2025